Myofibrillar remodelling in cardiac hypertrophy, heart failure and cardiomyopathies

Canadian Journal of Cardiology

Volumn 22, Issue 11, 2006, Pages 953-968

  Machackova, Jarmila ^a   Barta, Judit ^a   Dhalla, Naranjan S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cardiac gene expression; Cardiomyopathies; Congestive heart failure; Myocardial infarction; Myofibrillar alterations

Indexed keywords

CONTRACTILE PROTEIN; FUNCTIONAL GROUP; MUSCLE PROTEIN; REGULATOR PROTEIN;

CARDIOMYOPATHY; CELLULAR DISTRIBUTION; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART PERFORMANCE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MUSCLE ATROPHY; MUSCLE FIBRIL; NONHUMAN; OXIDATION; PHOSPHORYLATION; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; CARDIOMEGALY; HEART DISEASE; HEART MUSCLE; PATHOLOGY;

CARDIOMEGALY; CARDIOMYOPATHIES; GENE EXPRESSION REGULATION; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; MYOFIBRILS;

EID: 33750107298     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(06)70315-4     Document Type: Review

References (244)

1. Gregorio CC, Antin PB. To the heart of myofibril assembly. Trends Cell Biol 2000;10:355-62.
2. Gordon AM, Homsher E, Regnier M. Regulation of contraction in striated muscle. Physiol Rev 2000;80:853-924.
3. de Tombe PP. Cardiac myofilaments: Mechanics and regulation. J Biomech 2003;36:721-30.
4. Gaballa MA, Goldman S. Ventricular remodeling in heart failure. J Card Fail 2002;8(6 Suppl):S476-85.
5. Long CS, Ordahl CP, Simpson PC. Alpha 1-adrenergic receptor stimulation of sarcomeric actin isogetie transcription in hypertrophy of cultured rat heart muscle cells. J Clin Invest 1989;83:1078-82.
6. Swynghedauw B. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. Physiol Rev 1986;66:710-71.
7. Swynghedauw B. Cardiac Hypertrophy and Failure. London: INSERM/John Libbey Eurotext, 1990.
8. Nahrendorf M, Hu K, Fraccarollo D, et al. Time course of right ventricular remodeling in rats with experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003;284:H241-8.
9. Adachi S, Ito H, Tamamori M, Tanaka M, Marumo F, Hiroe M. Skeletal and smooth muscle alpha-actin mRNA in endomyocardial biopsy samples of dilated cardiomyopathy patients. Life Sci 1998;63:1779-91.
10. Suurmeijer AJ, Clement S, Francesconi A, et al. Alpha-actin isoform distribution in normal and failing human heart: A morphological, morphometric, and biochemical study. J Pathol 2003;199:387-97.
11. Hewett TE, Grupp IL, Grupp G, Robbins J. Alpha-skeletal actin is associated with increased contractility in the mouse heart. Circ Res 1994;74:740-6.
12. Lim DS, Roberts R, Marian AJ. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: Insight into the pathogenesis of phenotypes. J Am Coll Cardiol 2001;38:1175-80.
13. Bergen HR III, Ajtai K, Burghardt TP, Nepomuceno AI, Muddiman DC. Mass spectral determination of skeletal/cardiac actin isoform ratios in cardiac muscle. Rapid Commun Mass Spectrom 2003;17:1467-71.
14. Woodcock-Mitchell J, Mitchell JJ, Low RB, et al. Alpha-smooth muscle actin is transiently expressed in embryonic rat cardiac and skeletal muscles. Differentiation 1988;39:161-6.
15. Price KM, Littler WA, Cummins P. Human atrial and ventricular myosin light-chains subunits in the adult and during development. Biochem J 1980;191:571-80.
16. Barton PJ, Buckingham ME. The myosin alkali light chain proteins and their genes. Biochem J 1985;231:249-61.
17. Schaub MC, Tuchschmid CR, Srihari T, Hirzel HO. Myosin isoenzymes in human hypertrophic hearts. Shift in atrial myosin heavy chains and in ventricular myosin light chains. Eur Heart J 1984;(5Suppl F):85-93.
18. Auckland LM, Lambert SJ, Cummins P. Cardiac myosin light and heavy chain isotypes in tetralogy of Fallot. Cardiovasc Res 1986;20:828-36.
19. Hirzel HO, Tuchschmid CR, Schneider J, Krayenbuehl HP, Schaub MC. Relationship between myosin isoenzyme composition, hemodynamics, and myocardial structure in various forms of human cardiac hypertrophy. Circ Res 1985;57:729-40.
20. Sutsch G, Brunner UT, von Schulthess C, et al. Hemodynamic performance and myosin light chain-1 expression of the hypertrophied left ventricle in aortic valve disease before and after valve replacement. Circ Res 1992;70:1035-43.
21. Morano I, Ritter O, Bonz A, Timek T, Vahl CF, Michel G. Myosin light chain-actin interaction regulates cardiac contractility. Circ Res 1995;76:720-5.
22. Morano M, Zacharzowski U, Maier M, et al. Regulation of human heart contractility by essential myosin light chain isoforms. J Clin Invest 1996;98:467-73.
23. Schaub MC, Hefti MA, Zuellig RA, Morano I. Modulation of contractility in human cardiac hypertrophy by myosin essential light chain isoforms. Cardiovasc Res 1998;37:381-404.
24. Alpert NR, Gordon MS. Myofibrillar adenosine triphosphatase activity in congestive heart failure. Am J Physiol 1962;202:940-6.
25. Pope B, Hoh JF, Weeds A. The ATPase activities of rat cardiac myosin isoenzymes. FEBS Lett 1980;118:205-8.
26. VanBuren P, Harris DE, Alpert NR, Warshaw DM, Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro. Circ Res 1995;77:439-44.
27. Gupta M, Sueblinvong V, Raman J, Jeevanandam V, Gupta MP. Single-stranded DNA-binding proteins PURalpha and PURbeta bind to a purine-rich negative regulatory element of the alpha-myosin heavy chain gene and control transcriptional and translational regulation of the gene expression. Implications in the repression of alpha-myosin heavy chain during heart failure. J Biol Chem 2003;278:44935-48.
28. Reiser PJ, Portman MA, Ning XH, Schomisch Moravec C. Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles. Am J Physiol Heart Circ Physiol 2001;280:H1814-20.
29. Lewinter MM, Vanburen P. Myofilament remodeling during the progression of heart failure. J Card Fail 2002;8(6 Suppl):S271-5.
30. Harris DE, Work SS, Wright RK, Alpert NR, Warshaw DM. Smooth, cardiac and skeletal muscle myosin force and motion generation assessed by cross-bridge mechanical interactions in vitro. J Muscle Res Cell Motil 1994;15:11-9.
31. Ojamaa K, Petrie JF, Balkman C, Hong C, Klein I. Posttranscriptional modification of myosin heavy-chain gene expression in the hypertrophied rat myocardium. Proc Natl Acad Sci USA 1994;91:3468-72.
32. Gidh-Jain M, Huang B, Jain P, Gick G, El-Sherif N. Alterations in cardiac gene expression during ventricular remodeling following experimental myocardial infarction. J Mol Cell Cardiol 1998;30:627-37.
33. Mercadier JJ, Bouveret P, Gorza L, et al. Myosin isoenzymes in normal and hypertrophied human ventricular myocardium. Circ Res 1983;53:52-62.
34. Izumo S, Lompre AM, Matsuoka R, et al. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest 1987;79:970-7.
35. Haddad F, Bodell PW, Qin AX, Giger JM, Baldwin KM. Role of aritisense RNA in coordinating cardiac myosin heavy chain gene switching. J Biol Chem 2003;278:37132-8.
36. Chen Z, Higashiyama A, Yaku H, et al. Altered expression of troponin T isoforms in mild left ventricular hypertrophy in the rabbit. J Mol Cell Cardiol 1997;29:2345-54.
37. Piano MR, Bondmass M, Schwertz DW. The molecular and cellular pathophysiology of heart failure. Heart Lung 1998;27:3-19.
38. Wang X, Dhalla NS. Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure. Mol Cell Biochem 2000;214:131-55.
39. Schaub MC, Hefti MA, Harder BA, Eppenberger HM. Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes. J Mol Med 1997;75:901-20.
40. McNally EM, Kraft R, Bravo-Zehnder M, Taylor DA, Leinwand LA. Full-length rat alpha and beta cardiac myosin heavy chain sequences. Comparisons suggest a molecular basis for functional differences. J Mol Biol 1989;210:665-71.
41. Hefti MA, Harder BA, Eppenberger HM, Schaub MC. Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol 1997;29:2873-92.
42. Sugiura S, Kobayakawa N, Fujita H, et al. Comparison of unitary displacements and forces between 2 cardiac myosin isoforms by the optical trap technique: Molecular basis for cardiac adaptation. Circ Res 1998;82:1029-34.
43. Cooper G IV. Load and length regulation of cardiac energetics. Annu Rev Physiol 1990;52:505-22.
44. Geenen DL, Malhotra A, Liang D, Scheuer J. Ventricular function and contractile proteins in the infarcted overloaded rat heart. Cardiovasc Res 1991;25:330-6.
45. Malhotra A, Siri FM, Aronson R. Cardiac contractile proteins in hypertrophied and failing guinea pig heart. Cardiovasc Res 1992;26:153-61.
46. Krenz M, Sanbe A, Bouyet-Dalloz F, et al. Analysis of myosin heavy chain functionality in the heart. J Biol Chem 2003;278:17466-74.
47. Schier JJ, Adelstein RS. Structural and enzymatic comparison of human cardiac muscle myosins isolated from infants, adults, and patients with hypertrophic cardiomyopathy. J Clin Invest 1982;69:816-25.
48. Pagani ED, Alousi AA, Grant AM, Older TM, Dziuban SW Jr, Allen PD. Changes in myofibrillar content and Mg-ATPase activity in ventricular tissues from patients with heart failure caused by coronary artery disease, cardiomyopathy, or mitral valve insufficiency. Circ Res 1988;63:380-5.
49. Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest 1997;100:2362-70.
50. Miyata S, Minobe W, Bristow MR, Leinwand LA. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 2000;86:386-90.
51. Noguchi T, Camp P Jr, Alix SL, et al. Myosin from failing and non-failing human ventricles exhibit similar contractile properties. J Mol Cell Cardiol 2003;35:91-7.
52. Cooke R. Actomyosin interaction in striated muscle. Physiol Rev 1997;77:671-97.
53. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002;346:1357-65.
54. Gorza L, Mercadier JJ, Schwartz K, Thornell LE, Sartore S, Schiaffino S. Myosin types in the human heart. An immunofluorescence study of normal and hypertrophied atrial and ventricular myocardium. Circ Res 1984;54:694-702.
55. Bouvagnet P, Mairhofer H, Leger JO, Puech P, Leger JJ. Distribution pattern of alpha and beta myosin in normal and diseased human ventricular myocardium. Basic Res Cardiol 1989;84:91-102.
56. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 2001;104:2923-31.
57. Mittmann C, Eschenhagen T, Scholz H. Cellular and molecular aspects of contractile dysfunction in heart failure. Cardiovasc Res 1998;39:267-75.
58. Nguyen TT, Hayes E, Mulieri LA, et al. Maximal actomyosin ATPase activity and in vitro myosin motility are unaltered in human mitral regurgitation heart failure, Circ Res 1996;79:222-6.
59. Herron TJ, McDonald KS. Small amounts of alpha-myosin heavy chain isoform expression significantly increase power output of rat cardiac myocyte fragments. Circ Res 2002;90:1150-2.
60. Hilfiker-Kleiner D, Hilfiker A, Schieffer B, et al. TNFalpha decreases alphaMHC expression by a NO mediated pathway: Role of E-box transcription factors for cardiomyocyte specific gene regulation. Cardiovasc Res 2002;53:460-9.
61. Mercadier JJ, de la Bastie D, Menasche P, et al. Alpha-myosin heavy chain isoform and atrial size in patients with various types of mitral valve dysfunction: A quantitative study. J Am Coll Cardiol 1987;9:1024-30.
62. Alpert NR, Mulieri LA, Warshaw D. The failing human heart. Cardiovasc Res 2002;54:1-10.
63. Lowes BD, Minobe W, Abraham WT, et al. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 1997;100:2315-24.
64. Winegrad S, Wisnewsky C, Schwartz K. Effect of thyroid hormone on the accumulation of mRNA for skeletal and cardiac alpha-actin in hearts from normal and hypophysectomized rats. Proc Natl Acad Sci USA 1990;87:2456-60.
65. Nadal-Ginard B, Mahdavi V. Molecular basis of cardiac performance. Plasticity of the myocardium generated through protein isoform switches. J Clin Invest 1989;84:1693-700.
66. Schiaffino S, Reggiani C. Molecular diversity of myofibrillar proteins: Gene regulation and functional significance. Physiol Rev 1996;76:371-423.
67. James J, Robbins J. Molecular remodeling of cardiac contractile function. Am J Physiol 1997;273:H2105-18.
68. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-62.
69. Holtwick R, van Eickels M, Skryabin BV, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003;111:1399-407.
70. Fraccarollo D, Bauersachs J, Kellner M, Galuppo P, Ertl G. Cardioprotection by long-term ET(A) receptor blockade and ACE inhibition in rats with congestive heart failure: Mono-versus combination therapy. Cardiovasc Res 2002;54:85-94.
71. Min JY, Yang Y, Converso KL, et al. Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats. J Appl Physiol 2002;92:288-96.
72. Tanaka M, Hiroe M, Ito H, et al. Differential localization of atrial natriuretic peptide and skeletal alpha-actin messenger RNAs in left ventricular myocytes of patients with dilated cardiomyopathy. J Am Coll Cardiol 1995;26:85-92.
73. Boheler KR, Carrier L, de la Bastie D, et al. Skeletal actin mRNA increases in the human heart during ontogenic development and is the major isoform of control and failing adult hearts. J Clin Invest 1991;88:323-30.
74. Morano I, Hadicke K, Haase H, Bohm M, Erdmann E, Schaub MC. Changes in essential myosin light chain isoform expression provide a molecular basis for isometric force regulation in the failing human heart. J Mol Cell Cardiol 1997;29:1177-87.
75. Nakao K, Yasue H, Fujimoto K, et al. Increased expression and regional differences of atrial myosin light chain 1 in human ventricles with old myocardial infarction. Analyses using two monoclonal antibodies. Circulation 1992;86:1727-37.
76. Cummins P, Lambert SJ. Myosin transitions in the bovine and human heart. A developmental and anatomical study of heavy and light chain subunits in the atrium and ventricle. Circ Res 1986;58:846-58.
77. Trahair T, Yeoh T, Cartmill T, et al. Myosin light chain gene expression associated with disease states of the human heart. J Mol Cell Cardiol 1993;25:577-85.
78. Adamcova M, Pelouch V. Isoforms of troponin in normal and diseased myocardium. Physiol Res 1999;48:235-47.
79. 2+ sensitivity. J Mol Cell Cardiol 2002;34:469-82.
80. Anderson PA, Malouf NN, Oakeley AE, Pagani ED, Allen PD. Troponin T isoform expression in the normal and failing human left ventricle: A correlation with myofibrillar ATPase activity. Basic Res Cardiol 1992;87(Suppl 1):117-27.
81. Kameyama T, Chen Z, Bell SP, VanBuren P, Maughan D, LeWinter MM. Mechanoenergetic alterations during the transition from cardiac hypertrophy to failure in Dahl salt-sensitive rats. Circulation 1998;98:2919-29.
82. Perry SV. Troponin I: Inhibitor or facilitator. Mol Cell Biochem 1999;190:9-32.
83. Anderson PA, Malouf NN, Oakeley AE, Pagani ED, Allen PD. Troponin T isoform expression in humans. A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res 1991;69:1226-33.
84. Anderson PA, Greig A, Mark TM, et al. Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart. Circ Res 1995;76:681-6.
85. Townsend PJ, Barton PJ, Yacoub MH, Farza H. Molecular cloning of human cardiac troponin T isoforms: Expression in developing and failing heart. J Mol Cell Cardiol 1995;27:2223-36.
86. Mesnard L, Logeart D, Taviaux S, Diriong S, Mercadiet JJ, Samson F. Human cardiac troponin T: Cloning and expression of new isoforms in the normal and failing heart. Circ Res 1995;76:687-92.
87. Mesnard-Rouiller L, Mercadier JJ, Butler-Browne G, et al. Troponin T mRNA and protein isoforms in the human left ventricle: Pattern of expression in failing and control hearts. J Mol Cell Cardiol 1997;29:3043-55.
88. Nassar R, Malouf NN, Kelly MB, Oakeley AE, Anderson PA. Force-pCa relation and troponin T isoforms of rabbit myocardium. Circ Res 1991;69:1470-5.
89. 2+ sensitivity of skinned cardiac muscle contractility coincident with troponin T-band shifts in the diabetic rat. Circ Res 1995;76:600-6.
90. Solaro RJ, Gambassi G, Warshaw DM, et al. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res 1993;73:981-90.
91. 2+ sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res 2003;57:37-47.
92. Wang K, Ramirez-Mitchell R, Palter D. Titin is an extraordinarily long, flexible, and slender myofibrillar protein. Proc Natl Acad Sci USA 1984;81:3685-9.
93. Gregorio CC, Granzier H, Sorimachi H, Labeit S. Muscle assembly: A titanic achievement? Curr Opin Cell Biol 1999;11:18-25.
94. Haravuori H, Vihola A, Straub V, et al. Secondary calpain3 deficiency in 2q-linked muscular dystrophy: Titin is the candidate gene. Neurology 2001;56:869-77.
95. Labeit S, Kolmerer B. Titins: Giant proteins in charge of muscle ultrastructure and elasticity. Science 1995;270:293-6.
96. Helmes M, Trombitas K, Granzier H. Titin develops restoring force in rat cardiac myocytes. Circ Res 1996;79:619-26.
97. Granzier H, Helmes M, Trombitas K. Nonuniform elasticity of titin in cardiac myocytes: A study using immunoelectron microscopy and cellular mechanics. Biophys J 1996;70:430-42.
98. Freiburg A, Trombitas K, Hell W, et al. Series of exon-skipping events in the elastic spring region of titin as the structural basis for myofibrillar elastic diversity. Circ Res 2000;86:1114-21.
99. Cazorla O, Freiburg A, Helmes M, et al. Differential expression of cardiac titin isoforms and modulation of cellular stiffness. Circ Res 2000;86:59-67.
100. Wu Y, Labeit S, Lewinter MM, Granzier H. Titin: An endosarcomeric protein that modulates myocardial stiffness in DCM. J Card Fail 2002;8(6 Suppl):S276-86.
101. Neagoe C, Kulke M, del Monte F, et al. Titin isoform switch in ischemic human heart disease. Circulation 2002;106:1333-41.
102. Hein S, Scholz D, Fujitani N, et al. Altered expression of titin and contractile proteins in failing human myocardium. J Mol Cell Cardiol 1994;26:1291-306.
103. Elsasser A, Schlepper M, Klovekorn WP, et al. Hibernating myocardium: An incomplete adaptation to ischemia. Circulation 1997;96:2920-31.
104. Morano I, Hadicke K, Grom S, et al. Titin, myosin light chains and C-protein in the developing and failing human heart. J Mol Cell Cardiol 1994;26:361-8.
105. Weber KT. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation. Circulation 1997;96:4065-82.
106. Hein S, Kostin S, Heling A, Maeno Y, Schaper J. The role of the cytoskeleton in heart failure. Cardiovasc Res 2000;45:273-8.
107. Heling A, Zimmermann R, Kostin S, et al. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res 2000;86:846-53. (Erratum in 2000;87:167).
108. 2+-sensitivity of force is enhanced in failing human hearts. Cardiovasc Res 2003;57:505-14.
109. 2+ sensitivity in failing hearts. Am J Physiol Heart Circ Physiol 2001; 281:H637-46.
110. Wolff MR, Buck SH, Stoker SW, Greaser ML, Mentzer RM. Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: Role of altered beta-adrenergically mediated protein phosphorylation. J Clin Invest 1996;98:167-76.
111. Bodor GS, Oakeley AE, Allen PD, Crimmins DL, Ladenson JH, Anderson PA. Troponin I phosphorylation in the normal and failing adult human heart. Circulation 1997;96:1495-500.
112. Mittmann K, Jaquet K, Heilmeyer LM Jr. A common motif of two adjacent phosphoserines in bovine, rabbit and human cardiac troponin I. FEBS Lett 1990;273:41-5.
113. Zhang R, Zhao J, Mandveno A, Potter JD. Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ Res 1995;76:1028-35.
114. Solaro RJ, Van Eyk J. Altered interactions among thin filament proteins modulate cardiac function. J Mol Cell Cardiol 1996;28:217-30.
115. 2+-sensitivity of myofilaments in human heart failure. Cardiovasc Res 2003;57:5-7.
116. Dohet C, al-Hillawi E, Trayer IP, Ruegg JC. Reconstitution of skinned cardiac fibres with human recombinant cardiac troponin-I mutants and troponin-C. FEBS Lett 1995;377:131-4.
117. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
118. Dhalla NS, Dixon IM, Suzuki S, Kaneko M, Kobayashi A, Beamish RE. Changes in adrenergic receptors during the development of heart failure. Mol Cell Biochem 1992;114:91-5.
119. Moser DK. Pathophysiology of heart failure update: The role of neurohumoral activation in the progression of heart failure. AACN Clin Issues 1998;9:157-71.
120. Zakhary DR, Moravec CS, Stewart RW, Bond M. Protein kinase A (PKA)-dependent troponin-I phosphorylation and PKA regulatory subunits are decreased in human dilated cardiomyopathy. Circulation 1999;99:505-10.
121. Barta J, Toth A, Edes I, et al. Calpain-1-sensitive myofibrillar proteins of the human myocardium. Mol Cell Biochem 2005;278:1-8.
122. Reiffert S, Maytum R, Geeves M, et al. Characterization of the cardiac holotroponin complex reconstituted from native cardiac troponin T and recombinant I and C. Eur J Biochem 1999;261:40-7.
123. van der Velden J, de Jong JW, Owen VJ, Burton PB, Stienen GJ. Effect of protein kinase A on calcium sensitivity of force and its sarcomere length dependence in human cardiomyocytes. Cardiovasc Res 2000;46:487-95.
124. van der Velden J, Boontje NM, Papp Z, et al. Calcium sensitivity of force in human ventricular cardiomyocytes from donor and failing hearts. Basic Res Cardiol 2002;97(Suppl 1):I118-26.
125. Neumann J, Eschenhagen T, Jones LR, et al. Increased expression of cardiac phosphatases in patients with end-stage heart failure. J Mol Cell Cardiol 1997;29:265-72.
126. El-Armouche A, Pamminger T, Ditz D, Zolk O, Eschenhagen T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res 2004;61:87-93.
127. Neumann J, Gupta RC, Schmitz W, Scholz H, Naim AC, Watanabe AM. Evidence for isoproterenol-induced phosphorylation of phosphatase inhibitor-1 in the intact heart. Circ Res 1991;69:1450-7.
128. Gu X, Bishop SP. Increased protein kinase C and isozyme redistribution in pressure-overload cardiac hypertrophy in the rat. Circ Res 1994;75:926-31.
129. 2+-sensitive isoforms in the failing human heart. Circulation 1999;99:384-91.
130. 2+-dependent protein kinase. Biochem J 1983;209:189-95.
131. Venema RC, Kuo JF. Protein kinase C-mediated phosphorylation of troponin I and C-protein in isolated myocardial cells is associated with inhibition of myofibrillar actomyosin MgATPase. J Biol Chem 1993;268:2705-11.
132. 2+-stimulated MgATPase of reconstituted actomyosin S-1. J Biol Chem 1995;270:25445-54.
133. Jideama NM, Noland TA Jr, Raynor RL, et al. Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties. J Biol Chem 1996;271:23277-83.
134. Noland TA Jr, Raynor RL, Jideama NM, et al. Differential regulation of cardiac actomyosin S-1 MgATPase by protein kinase C isozyme-specific phosphorylation of specific sites in cardiac troponin I and its phosphorylation site mutants. Biochemistry 1996;35:14923-31.
135. 2+-stimulated MgATPase activity in reconstituted actomyosin and isolated myofibrils, and decreases actin-myosin interactions. J Mol Cell Cardiol 1993;25:53-65.
136. Sumandea MP, Pyle WG, Kobayashi T, de Tombe PP, Solato RJ. Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T. J Biol Chem 2003;278:35135-44.
137. 2+ sensitivity and ATPase activity in the mouse myocardium. J Physiol 2003;552:845-57.
138. Clement O, Puceat M, Walsh MP, Vassort G. Protein kinase C enhances myosin light-chain kinase effects on force development and ATPase activity in rat single skinned cardiac cells. Biochem J 1992;285:311-7.
139. 2+-stimulated actomyosin MgATPase activity. Biochem Biophys Res Commun 1993;193:254-60.
140. Venema RC, Raynor RL, Noland TA Jr, Kuo JF. Role of protein kinase C in the phosphorylation of cardiac myosin light chain 2. Biochem J 1993;294:401-6.
141. Gautel M, Zuffardi O, Freiburg A, Labeit S. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: A modulator of cardiac contraction? EMBO J 1995;14:1952-60.
142. Lim MS, Sutherland C, Walsh MP Phosphorylation of bovine cardiac C-protein by protein kinase C. Biochem Biophys Res Commun 1985;132:1187-95.
143. Winegrad S. Cardiac myosin binding protein C. Circ Res 1999;84:1117-26.
144. McClellan G, Kulikovskaya I, Winegrad S. Changes in cardiac contractility related to calcium-mediated changes in phosphorylation of myosin-binding protein C. Biophys J 2001;81:1083-92.
145. Garvey JL, Kranias EG, Solaro RJ. Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts. Biochem J 1988;249:709-14.
146. Weisberg A, Winegrad S. Relation between crossbridge structure and actomyosin ATPase activity in rat heart. Circ Res 1998;83:60-72.
147. van der Velden J, Klein LJ, Zaremba R, et al. Effects of calcium, inorganic phosphate, and pH on isometric force in single skinned cardiomyocytes from donor and failing human hearts. Circulation 2001;104:1140-6.
148. Kobayashi N, Horinaka S, Mita S, et al. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res 2002;55:757-67.
149. Morano I, Arndt H, Gartner C, Ruegg JC. Skinned fibers of human atrium and ventricle: Myosin isoenzymes and contractility. Circ Res 1988;62:632-9.
150. Liu X, Shao Q, Dhalla NS. Myosin light chain phosphorylation in cardiac hypertrophy and failure due to myocardial infarction. J Mol Cell Cardiol 1995;27:2613-21.
151. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997;96:2953-8.
152. 2+-sensitivity. Mol Cell Biochem 1999; 194:301-13.
153. Vatta M, Stetson SJ, Perez-Verdia A, et al. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet 2002;359:936-41.
154. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloptoteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000;102:1944-9.
155. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-9.
156. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-41.
157. Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, Hajjar RJ. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci USA 2002;99:6252-6.
158. Bing OH. Hypothesis: Apoptosis may be a mechanism for the transition to heart failure with chronic pressure overload. J Mol Cell Cardiol 1994;26:943-8.
159. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999;79:609-34.
160. Tsutsui H. Novel pathophysiological insight and treatment strategies for heart failure. Circ J 2004;68:1095-103.
161. Goll DE, Thompson VF, Taylor RG, Christiansen JA. Role of the calpain system in muscle growth. Biochimie 1992;74:225-37.
162. Cheung PY, Sawicki C, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000;101:1833-9.
163. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: A new approach to prevent heart failure? Circ Res 2001;89:201-10.
164. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543-9.
165. Frazier OH, Benedict CR, Radovancevic B, et al. Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg 1996;62:675-81.
166. Muller J, Wallukat G, Weng YG, et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 1997;96:542-9.
167. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998;97:2316-22.
168. Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998;98:656-62.
169. Hetzer R, Muller J, Weng Y, Wallukat G, Spiegelsberger S, Loebe M. Cardiac recovery in dilated cardiomyopathy by unloading with a left ventricular assist device. Ann Thorac Surg 1999;68:742-9.
170. de Jonge N, van Wichen DF, Schipper ME, et al. Left ventricular assist device in end-stage heart failure: Persistence of structural myocyte damage after unloading. An immunohistochemical analysis of the contractile myofilaments. J Am Coll Cardiol 2002;39:963-9.
171. Franz WM, Muller OJ, Katus HA. Cardiomyopathies: From genetics to the prospect of treatment. Lancet 2001;358:1627-37.
172. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996;93:841-2.
173. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
174. Poetter K, Jiang H, Hassanzadeh S, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle, Nat Genet 1996;13:63-9.
175. Vikstrom KL, Leinwand LA. Contractile protein mutations and heart disease. Curt Opin Cell Biol 1996;8:97-105,
176. Towbin JA. The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol 1998;10:131-9.
177. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell 2001;104:557-67.
178. Olson TM, Michels VV, Thibodeau SN, Tai YS, Keating MT. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998;280:750-2.
179. Kokado H, Shimizu M, Yoshio H, et al. Clinical features of hypertrophic cardiomyopathy caused by a Lys183 deletion mutation in the cardiac troponin I gene. Circulation 2000;102:663-9.
180. 2+ regulation of thin filament motility. Biochem Biophys Res Commun 1997; 236:760-4.
181. Cuda G, Pate E, Cooke R, Sellers JR. In vitro actin filament sliding
182. Lombardi R, Betocchi S. Aetiology and pathogenesis of hypertrophic cardiomyopathy. Acta Paediatr Suppl 2002;91:10-4.
183. Sweeney HL, Straceski AJ, Leinwand LA, Tikunov BA, Faust U. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J Biol Chem 1994;269:1603-5.
184. Barta J, Toth A, Jaquet K, Redlich A, Edes I, Papp Z. Calpain-1-dependent degradation of troponin I mutants found in familial hypertrophic cardiomyopathy. Mol Cell Biochem 2003;251:83-8.
185. Bonne G, Carrier L, Richard P, Hainque B, Schwartz K. Familial hypertrophic cardiomyopathy: From mutations to functional defects. Circ Res 1998;83:580-93.
186. Cuda C, Fananapazir L, Epstein ND, Sellers JR. The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil 1997;18:275-83.
187. McNally E, Allikian M, Wheeler MT, Mislow JM, Heydemann A. Cytoskeletal defects in cardiomyopathy. J Mol Cell Cardiol 2003;35:231-41.
188. Keller DI, Coirault C, Rau T, et al. Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. J Mol Cell Cardiol 2004;36:355-62.
189. 2+ regulation of thin filament motility. Biochem Biophys Res Commun 1997; 236:760-4.
190. Witt CC, Gerull B, Davies MJ, Centner T, Linke WA, Thierfelder L. Hypercontractile properties of cardiac muscle fibers in a knock-in mouse model of cardiac myosin-binding protein-C. J Biol Chem 2001;276:5353-9.
191. Kabaeva ZT, Perrot A, Wolter B, et al. Systematic analysis of the regulatory and essential myosin light chain genes: Genetic variants and mutations in hypertrophic cardiomyopathy. Eur J Hum Genet 2002;10:741-8.
192. Abdelaziz AI, Segaric J, Bartsch H, et al. Functional characterization of the human atrial essential myosin light chain (hALC-1) in a transgenic rat model. J Mol Med 2004;82:265-74.
193. Olson TM, Kishimoto NY, Whitby FG, Michels VV. Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. J Mol Cell Cardiol 2001;33:723-32.
194. Haase D, Lehmann MH, Korner MM, Korfer R, Sigusch HH, Figulla HR. Identification and validation of selective upregulation of ventricular myosin light chain type 2 mRNA in idiopathic dilated cardiomyopathy. Eur J Heart Fail 2002;4:23-31.
195. Prabhakar R, Boivin GP, Grupp IL, et al. A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. J Mol Cell Cardiol 2001;33:1815-28. (Erratum in 2001;33:2061).
196. Gaffin RD, Gokulan K, Sacchettini JC, et al. Charged residue changes in the carboxy-terminus of alpha-tropomyosin alter mouse cardiac muscle contractility. J Physiol 2004;556:531-43.
197. Muthuchamy M, Boivin GP, Grupp IL, Wieczorek DF. Beta-tropomyosin overexpression induces severe cardiac abnormalities. J Mol Cell Cardiol 1998;30:1545-57.
198. 2+, strong cross-bridge binding, and protein phosphorylation. J Biol Chem 1996;271:11611-4.
199. 2+ and altered dynamics of contraction and relaxation in transgenic cardiac cells that express beta-tropomyosin. Circ Res 1999;84:745-51.
200. Jagatheesan G, Rajan S, Petrashevskaya N, et al. Functional importance of the carboxyl-terminal region of striated muscle tropomyosin. J Biol Chem 2003;278:23204-11.
201. Regitz-Zagrosek V, Erdmann J, Wellnhofer E, Raible J, Fleck E. Novel mutation in the alpha-tropomyosin gene and transition from hypertrophic to hypocontractile dilated cardiomyopathy. Circulation 2000;102:E112-6.
202. Kimura A, Harada H, Park JE, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997;16:379-82.
203. Elliott K, Watkins H, Redwood CS. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem 2000;275:22069-74.
204. Takahashi-Yanaga F, Morimoto S, Harada K, et al. Functional consequences of the mutations in human cardiac troponin I gene found in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001;33:2095-107.
205. James J, Zhang Y, Osinska H, et al. Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. Circ Res 2000;87:805-11.
206. Lang R, Gomes AV, Zhao J, Housmans PR, Miller T, Potter JD. Functional analysis of a troponin I (R145G) mutation associated with familial hypertrophic cardiomyopathy. J Biol Chem 2002;277:11670-8.
207. Frey N, Franz WM, Gloeckner K, et al. Transgenic rat hearts expressing a human cardiac troponin T deletion reveal diastolic dysfunction and ventricular arrhythmias. Cardiovasc Res 2000;47:254-64.
208. Javadpour MM, Tardiff JC, Pinz I, Ingwall JS. Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. J Clin Invest 2003;112:768-75.
209. Takahashi-Yanaga F, Ohtsuki I, Morimoto S. Effects of troponin T mutations in familial hypertrophic cardiomyopathy on regulatory functions of other troponin subunits. J Biochem (Tokyo) 2001;130:127-31.
210. Sweeney HL, Feng HS, Yang Z, Watkins H. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: Insights into disease pathogenesis and troponin function. Proc Natl Acad Sci USA 1998;95:14406-10.
211. Takeda N. Cardiomyopathy: Molecular and immunological aspects (review). Int J Mol Med 2003;11:13-6.
212. 2+ sensitivity and inhibition of force development. Insights into the role of troponin T isoforms in the heart. J Biol Chem 2002;277:35341-9.
213. Robinson P, Mirza M, Knott A, et al. Alterations in thin filament regulation induced by a human cardiac troponin T mutant that causes dilated cardiomyopathy are distinct from those induced by troponin T mutants that cause hypertrophic cardiomyopathy. J Biol Chem 2002;277:40710-6.
214. Fonarow CC. Dilated cardiomyopathy can result from mutations in sarcomere protein genes. Rev Cardiovasc Med 2001;2:103-4.
215. Bowles NE, Bowles KR, Towbin JA. The "final common pathway" hypothesis and inherited cardiovascular disease. The role of cytoskeletal proteins in dilated cardiomyopathy. Herz 2000;25:168-75.
216. Kamisago M, Sharma SD, DePalma SR, et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000;343:1688-96.
217. Barrans JD, Allen PD, Stamatiou D, Dzau VJ, Liew CC. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 2002;160:2035-43.
218. Mogensen J, Klausen IC, Pedersen AK, et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999;103:R39-43.
219. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50:509-17.
220. Ferlini A, Sewry C, Melis MA, Mateddu A, Muntoni F. X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord 1999;9:339-46.
221. Franz WM, Muller M, Muller OJ, et al. Association of nonsense mutation of dystrophin gene with disruption of sarcoglycan complex in X-linked dilated cardiomyopathy. Lancet 2000;355:1781-5.
222. Badorff C, Lee GH, Lamphear BJ, et al. Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999;5:320-6.
223. Badorff C, Lee GH, Knowlton KU. Enteroviral cardiomyopathy: Bad news for the dystrophin-glycoptotein complex. Herz 2000;25:227-32.
224. Daehmlow S, Erdmann J, Knueppel T, et al. Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem Biophys Res Commun 2002;298:116-20.
225. Sehnert AJ, Huq A, Weinstein BM, Walker C, Fishman M, Stainier DY. Cardiac troponin T is essential in sarcomere assembly and cardiac contractility. Nat Genet 2002;31:106-10.
226. Tardiff JC, Hewett TE, Palmer BM, et al. Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest 1999;104:469-81.
227. 2+ regulatory properties of reconstituted thin filaments depend on the ratio of mutant to wild-type protein. Circ Res 2000; 86:1146-52.
228. 2+-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy. Proc Natl Acad Sci USA 2002;99:913-8.
229. 2+ desensitization. J Mol Cell Cardiol 2003;35:1421-7.
230. Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: Histopathological features of sudden death in cardiac troponin T disease. Circulation 2001;104:1380-4.
231. Venkatraman G, Harada K, Gomes AV, Kerrick WG, Potter JD. Different functional properties of troponin T mutants that cause dilated cardiomyopathy. J Biol Chem 2003;278:41670-6.
232. Itoh-Satoh M, Hayashi T, Nishi H, et al. Titin mutations as the molecular basis for dilated cardiomyopathy. Biochem Biophys Res Commun 2002;291:385-93.
233. Gerull B, Gramlich M, Atherton J, et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 2002;30:201-4.
234. Wang X, Osinska H, Dom GW Jr, et al. Mouse model of desmin-related cardiomyopathy. Circulation 2001;103:2402-7.
235. Wang X, Osinska H, Klevitsky R, et al. Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. Circ Res 2001;89:84-91.
236. Dalakas MC, Park KY, Semino-Mora C, Lee HS, Sivakumar K, Goldfarb LG. Desmin myopathy, a skeletal myopathy with cardiomyopathy caused by mutations in the desmin gene. N Engl J Med 2000;342:770-80.
237. Towbin JA. Cardiomyopathy and heart transplantation in children. Curr Opin Cardiol 2002;17:274-9.
238. Chien KR. Genotype, phenotype: Upstairs, downstairs in the family of cardiomyopathies. J Clin Invest 2003;111:175-8. (Erratum in 2003;11:1433).
239. Abraham WT, Gilbert EM, Lowes BD, et al. Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med 2002;8:750-60.
240. Mann DL. Mechanisms and models in heart failure: A combinatorial approach. Circulation 1999;100:999-1008.
241. Wang J, Liu X, Ren B, Rupp H, Takeda N, Dhalla NS. Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction. J Mol Cell Cardiol 2002;34:847-57.
242. Wang J, Guo X, Dhalla NS. Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. Biochem Biophys Acta 2004;1690:177-84.
243. Guo X, Saini HK, Wang J, Gupta SK, Goyal RK, Dhalla NS. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system. Expert Rev Cardiovasc Ther 2005;3:717-32.
244. Machackova J, Barta J, Dhalla NS. Molecular defects in cardiac myofibrillar proteins due to thyroid hormone imbalance and diabetes. Can J Physiol Pharmacol 2005;83:1071-91.